

SUPERNUS PHARMACEUTICALS INC
 Form 4
 March 26, 2013

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
BIGHAM MICHAEL

(Last) (First) (Middle)

C/O ABINGWORTH
 MANAGEMENT INC, 890
 WINTER STREET, SUITE 150

(Street)

WALTHAM, MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
**SUPERNUS
 PHARMACEUTICALS INC
 [SUPN]**

3. Date of Earliest Transaction
 (Month/Day/Year)
 03/20/2013

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)
				(A) or (D)	Price		
Common Stock	03/20/2013		P	5,000	A \$ 5,172 (1)	5,000	I By Beatrice Emerson Bigham Trust U/A DTD 2/28/2001
Common Stock	03/20/2013		P	5,000	A \$ 5,195 (2)	5,000	I By Cabot Forbes Bigham

									Trust U/A DTD 10/11/1996
Common Stock	03/20/2013		P	10,000	A	\$ 5.264 <u>(3)</u>	10,000	I	By Michael F Bigham CRUT U/A DTD 11/23/1994
Common Stock	03/22/2013		P	15,000	A	\$ 5.653 <u>(4)</u>	25,000	I	By Michael F Bigham CRUT U/A DTD 11/23/1994

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Pri Deriv Secur (Instr.	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	\$ 7.9					02/05/2014	02/05/2023	Common Stock	8,722

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

BIGHAM MICHAEL
C/O ABINGWORTH MANAGEMENT INC X
890 WINTER STREET, SUITE 150
WALTHAM, MA 02451

Signatures

/s/ Gregory S. Patrick, as
attorney-in-fact 03/26/2013

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$5.11 to \$5.20, inclusive. The Reporting Person undertakes to provide to any security holder of Supernus Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) through (4).
- (2) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from \$5.17 to 5.20, inclusive.
- (3) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from \$5.18 to 5.49, inclusive.
- (4) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from \$5.53 to 5.68, inclusive.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.